The short answer
Hire for AI that already runs in production inside a regulated P&L. A model-building résumé is the wrong filter. Only about 5% of organizations get generative AI into production with measurable P&L impact (MIT NANDA, The GenAI Divide, 2025), and the gap comes from integration and operations, not from the models. A good fractional CAIO for a healthcare services company owns that gap: use cases tied to the value creation plan, governance that holds up in a HIPAA review, and workflows shipped with an audit trail.
The JD most searches write (and why it misses)
Read ten Fractional CAIO postings for PE-backed healthcare platforms and you'll see the same profile: fifteen years of technology leadership, a PhD in machine learning, hands-on deep learning, computer vision and MLOps.
That's the profile of someone who builds models. Most healthcare services companies don't need new models. They need the models that already exist (and are a commodity now) wired into intake, scheduling, revenue cycle and patient communication, with a human in the loop wherever a wrong answer has clinical or regulatory consequences.
The pilots that die don't die in the lab. They die in the handoff to operations: nobody owns the workflow, nobody owns the number, and compliance sees it for the first time a week before launch.
The profile that moves the number
Must have:
- AI running in production (past the pilot) inside a regulated business, with actual users and actual volume.
- A revenue or cost number they personally owned, and the ability to name what their last AI deployment moved.
- Governance that works in practice: confirmation gates, human escalation, and an audit trail a regulator or a board can read.
- Fluency in healthcare operations (intake, provider capacity, the patient journey), so AI lands where the work happens.
Can partner for: deep ML and model-building. If the roadmap needs custom models, the CAIO hires or contracts that technical lead and directs them. The reverse almost never works.
The first 90 days
- Days 1-30: inventory every AI use case (live, piloted, imagined) and score each against the value creation plan. Most portfolios have three that matter and twelve that don't.
- Days 31-60: ship two or three workflows to production with a human in the loop and an append-only audit trail. Measure against a baseline set before launch.
- Days 61-90: stand up a governance committee that actually meets, with a written policy for what AI may decide, what it may only suggest, and what it never touches.
The one question that screens fast
"What KPI did your last AI deployment move, and by how much?"
If the answer is a model accuracy score, you're talking to a builder. If the answer is conversion, cost per case, time to appointment or recovered revenue, you're talking to an operator. Healthcare services companies need the operator in the CAIO seat.
Where I fit
I'm the operator who gets AI into production and ties it to the numbers. At HelixVM (DTC telehealth) I built the operating engine behind 100K+ patient encounters over ~18 months, where human-in-the-loop AI intake lifted conversion 40% and cut appointment time 50%, with a human still in the loop (the HelixVM case). At Fenix Pharma I shipped a production AI sales agent in 13 days from idea to production (Claude and our Odoo ERP over WhatsApp), with confirmation gates, human escalation and an append-only audit trail; it recovered ~45% of warm leads on a live channel (the AI agent case). I've owned the P&L those systems sit in.
My rule for AI in healthcare is simple: it prepares and suggests, a human decides, and every step leaves an audit trail.
Weighing a fractional executive against a full-time hire? Here's the math.